The rush to CRISPR Cas9 is due to the possibility of potential billions in the business of CRISPR technology. It is exemplified by the topical advent of CRISPR start-up firms, initial public offerings (IPOs), and venture capital funding rounds that are rising at astounding rates, and savvy investors have secured extensive and, in some cases, exponential rewards.

CRISPR solutions are transforming four priority markets of therapeutic development, agricultural biotechnology, industrial biotechnology, basic and applied biological research and these markets are receiving huge investments from prominent firms.

In our newly published CRISPR Cas9 market research report, AheadIntel identifies following major significant active companies in the field of CRISPR-Cas9 Market focused on the clinical as well as non-clinical applications of CRISPR-Cas9 technology:

Addgene

Agilent Technologies Inc.

Applied Biological Materials Inc.

ATUM (formerly DNA2.0)

Astrazeneca

Beam Therapeutics

BASF

Bayer AG

Calyxt Inc.

Caribou Biosciences

Casebia Therapeutics

Crispr Therapeutics

Cellectis

Editas Medicine

Genecopeia

Genscript Horizon Discovery (Dharmacon)

Intellia Therapeutics

New England Biolabs

Novartis

Origene Technologies Inc

Sigma Aldrich (acquired by Merck)

System Biosciences

Takara Bio USA, Inc. (formerly Clontech Laboratories)

Thermo Fisher Scientific

Toolgen Inc

Transposagen Biopharmaceutical

Large biotech companies and pharmaceuticals like Novartis, Vertex, Bayer AG have skin in the CRISPR game exploring novel techniques to evolve their drug discovery and development processes, and forming strategic alliances with crucial CRISPR technology companies to devise gene-based therapies for various genetic diseases.

Evolution of CRISPR-Cas9 technology has revolutionized gene editing playing field. Not limited to its use as a therapeutic tool, the pharmaceutical industry has found a game changer for drug discovery and development. CRISPR provides the opportunity to study and alter all types of cell in the human body at a commercially viable pace and cost.

To know more about market potential of CRISPR Cas9 tool visit- CRISPR Cas9 Market Report